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Background: Dextran-40 is effective in reducing postoperative Doppler-detectable embolization in patients undergoing
carotid endarterectomy (CEA). Dextrans are thought to have antithrombotic and antiplatelet effects. The mode of action
is unclear. In rats, dextran blocks uptake of tissue plasminogen activator (tPA) by mannose-binding receptors. Because
this would have the effect of enhancing endogenous fibrinolysis, we explored this effect of dextran-40 on fibrinolysis in
man.
Methods: Twenty patients undergoing endovascular stenting for abdominal aortic aneurysm were randomized to receive
100mL of 10% dextran-40 or saline, over 1 hour, during their operation in addition to heparin. Blood samples were taken
preoperatively, intraoperatively (immediately after operative procedure), and 24 hours postoperatively. Thrombi were
formed in a Chandler loop and used to assess endogenous fibrinolysis over 24 hours, measured as the fall in thrombus
weight, and the release of fluorescently labelled fibrinogen from the thrombus. Plasma samples were analyzed for markers
of fibrinolysis; plasmin-antiplasmin (PAP), PAI-1, and t-PA, and for functional von Willebrand factor (vWF). Platelet
response to thrombin and other agonists was measured by flow cytometry.
Results: Thrombi formed ex vivo from the intraoperative blood samples from the dextran-treated patients exhibited
significantly greater fibrinolysis vs preoperative samples, seen both as a significantly greater percentage reduction in
thrombus weight (from 34.7% to 70.6% reduction) and as an 175% increase in the release of fluorescence (P < .05).
Fibrinolysis returned to baseline levels the next day. No change was seen in the saline-treated group. Plasma levels of PAP
and PAI-1 increased significantly postoperatively in the dextran-treated group vs the saline group (P < .05). The
postoperative level of functional VWF was significantly lower in the dextran-treated group vs controls. A specific
reduction occurred in the platelet response to thrombin, but not to other agonists, in the intraoperative samples from the
dextran-treated group (11.1% vs 37.1%; P  .022), which was not seen in the controls.
Conclusions: These data are consistent with a rise in plasmin due to dextran blockade of tPA uptake in vivo, leading to
enhanced fibrinolysis, cleavage of vWF and of the platelet protease-activated receptor-1 (PAR-1) thrombin receptor. This
suggests that dextran exerts a combined therapeutic effect, enhancing endogenous fibrinolysis, whilst also reducing
platelet adhesion to vWF and platelet activation by thrombin. The proven antithrombotic efficacy of low-dose dextran in
carotid surgery may be applicable to wider therapeutic use. ( J Vasc Surg 2008;48:715-22.)
Clinical Relevance: Dextran-40 is an effective therapeutic agent in the reduction of thromboembolic events after carotid
surgery, but its mechanism of action is unclear. We describe a laboratory study of the effect of dextran-40 in man that
clearly demonstrates that dextran-40 enhances fibrinolysis through a mechanism that is compatible with blockade of
uptake of tissue plasminogen activator in vivo. This study was conducted in patients undergoing aortic aneurism repair
for logistic reasons, but the data support the use of dextran-40 in patents undergoing carotid endarterectomy and may
suggest wider applications for the use of dextran to augment fibrinolysis/thrombolysis in other thrombotic diseases.Dextran has been used since World War II as a plasma
expander.1 From the 1950s onwards, reports have emerged
suggesting an effect of dextran on the hemostatic system, in
particular in prolonging bleeding time.2-4 The exact mech-
anism of action has remained unknown, however.
In 1995 the Vascular Surgery Unit at the Leicester
Royal Infirmary started routinely treating patients un-
dergoing carotid endarterectomy (CEA) with low-dose
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doi:10.1016/j.jvs.2008.04.008dextran-40 (20 to 40 mL/h, 10% dextran-40) if transcra-
nial Doppler monitoring revealed that significant numbers
of emboli were produced after CEA.5 Since the introduc-
tion of this policy, 500 consecutive operations have been
done without a single postoperative stroke.5 On adminis-
tration of dextran-40, the numbers of emboli fall steadily
within the first hour6; however, the mechanism of action
that underlies this effect is unclear.
Reports of an effect of dextran on the hemostatic
system span the past 50 years and cover a range of seem-
ingly disparate observations. Studies from the 1960s in hu-
mans and in dogs reported that dextran-70 infusions reduced
platelet adhesiveness, increased bleeding time and coagulation
time, and produced significant hemodilution.7-10 Greater ef-
fects were observed with high-molecular-weight dextrans.9,10
Studies in the 1970s demonstrated that these effects
might be partly attributed to a reduction in vonWillebrand
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4 to 6 hours after infusion. Reduced levels of vWF were
thought to be responsible for reduced stability of thrombi
formed in a Chandler loop with blood from healthy human
volunteers given 500mL dextran-70.14 These observations
and others investigating thrombus formation in vivo in
rabbits15,16 also suggested that dextran may be affecting
the fibrinolytic system, and a small number of studies from
the 1980s and 1990s supported this hypothesis. For exam-
ple, Carlin et al17 observed an increase in fibrinolytic activ-
ity in patients given 500 mL of 6% dextran-70 during the
postoperative period, and similar effects have been reported
in rabbits.18 More recently, Eriksson and Saldeen (1995)19
demonstrated that in patients undergoing elective surgery,
an infusion of 250 mL or 500 mL of 6% dextran-70 led to
a significant increase in tissue plasminogen activator (tPA)
activity and antigen, with a concomitant reduction in plas-
minogen activator inhibitor type 1 (PAI-1). However,
none of the effects seen in vivo have been reliably replicated
when dextran is added to blood in vitro.
A possible explanation for the in vivo effect of dextran
comes from the observation by Noorman et al20 that
dextran-40 and dextran-70 given to rats blocked the uptake
of tPA by the mannose receptor on rat liver endothelial
cells, inhibiting clearance of tPA from the circulation. It is
not clear whether similar mechanisms apply in humans
and with the doses of dextran-40 (20 to 40 mL of 10%
dextran-40 per hour) used to prevent postoperative throm-
boembolic complications in patients undergoing CEA. At
these levels hemodilution is not a significant factor. We
therefore explored the effect of dextran-40 in a group of
patients undergoing endovascular stenting for aortic aneu-
rysm repair, who were randomized to receive dextran-40 or
saline, to enable systematic study of a variety of measures of
hemostatic and fibrinolytic function.
METHODS
Subjects and study design. The study was designed
as a randomized, double-blind, controlled trial in 20 con-
secutive men undergoing elective endovascular stenting for
abdominal aortic aneurysm at the Leicester Royal Infir-
mary. These patients were studied in preference to patients
undergoing CEA because they provided a group amenable
to randomization and systematic study. Treatment of all
patients undergoing CEA with dextran can result in an
increased risk of bleeding,21 so current practice in Leicester
is to treat only those patients who generate a high number
of postoperative emboli.6 Therefore a prospective random-
ized trial in CEA patients was considered to pose an unac-
ceptable risk of causing bleeding complications. The study
was approved by the Ethical Practices Committee at the
Leicester Royal Infirmary, and all subjects gave written
informed consent.
Exclusion criteria included a history of a bleeding ab-
normality, cancer, renal disease, or any medication that
would significantly affect fibrinolysis. Consecutive patients
that met the inclusion criteria were randomized to receive
either 100 mL of 10% dextran-40 (Baxter, Newbury, UK)for 1 hour during the operation or an equivalent volume of
saline (0.9%). Randomization was by sealed envelopes pre-
pared by a research nurse independent of the study, and the
laboratory staff was blinded to the treatment.
All patients received unfractionated heparin infused
through the arterial catheter before operation and dextran.
Patients were standardized to 150 mg aspirin as the sole
antiplatelet drug before surgery, and platelet aggregation in
response to arachidonic acid showed all patients were re-
sponding (20% aggregation). No differences were noted
in the activated partial thromboplastin time or international
normalized ratio measurements between the groups.
The two groups of men were similar in age (71.7 8.6
years saline group vs 72.8  4.3 years dextran group; P 
.19), body weight (85.8  14.9 vs 81.3  10.0 kg; P 
.50), disease profile, and medication (P  .15 for all).
Platelet and leucocyte counts for the saline group and
dextran group were also similar (217  46 vs 216  30 
106/mL, P  .93; and 8.1  2.1vs 6.8  1.6  106/mL,
P  .18), as was plasma fibrinogen (2.98  0.81 g/L vs
2.75  0.52 g/L; P  .54). Hemoglobin was significantly
lower in the saline group at the start of their operation
(13.15  1.88 g/L vs 14.78  1.04 g/L; P  .04) and
remained lower at the end (10.22  2.51 g/L vs 12.61 
1.24 g/L; P  .03), although blood loss and fluid use was
similar in both groups.
Blood samples were taken at three time points: (1)
preoperation, after anaesthetic but before the start of the
operation, before heparin administration, and before
dextran or saline infusion; (2) intraoperation, at the end
of the 1-hour dextran infusion; and (3) postoperation,
on the morning after the operation. Blood was collected
from the arterial catheter into Vacutainer tubes (BD UK
Ltd, Oxford, UK) containing either CTAD (citrate, theoph-
ylline, adenosine and dipyridamole), or tris-sodium citrate
(0.105M; BD).
Generation of thrombi and measurement of fibri-
nolysis ex vivo. Thrombi were generated from whole
blood in a Chandler loop, using a method previously de-
scribed.22-24 Aliquots of 0.9 mL of citrated blood were
supplemented with 50 L of 1 mg/mL fluorescein isothio-
cyanate (FITC)-fibrinogen (prepared in house24), recalci-
fied, and placed into polythene tubing 45-cm long. The
ends were joined and the loops were rotated at 37 rpm for
90 minutes, resulting in an initial shear rate of 19.2 dynes/
cm2, rising to 500 dynes/cm2 during thrombus forma-
tion. Samples were run in duplicate, and the resultant
thrombus was removed, blotted, and weighed. To assess
fibrinolysis the thrombi were incubated inHanks’ buffer for
24 hours at 37°C. The supernatant was removed, and the
fluorescence released from the thrombi was measured in a
Spectrofluorophotometer (RF-5001PC; Shimadzu, Kyoto,
Japan). Loss of fluorescence was expressed in arbitrary
fluorescent units per milligram initial thrombus weight.
The remaining thrombi were blotted and reweighed to
calculate the loss of thrombus weight, which was the per-
centage fall in weight during 24 hours.
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dextran-40 was added to preoperation blood samples at a
comparable concentration to that being infused to patients
(20 L/mL) before generation of Candler loop thrombi.
In a separate experiment, recombinant tPA (rtPA; Activase,
Alterplase, Genentech Inc, San Francisco, Calif) was added
to the blood at final concentrations of 0.0015 to 15 g/
mL, before formation of the thrombi, to assess the effect of
tPA on endogenous fibrinolysis.
Measurement of fibrinolytic factors in plasma.
Blood was collected into CTAD, and plasma was immedi-
ately separated by double centrifugation of 20 minutes at
1550g and 4°C, followed by 10minutes at 9300g. Aliquots
of plasma were immediately frozen and stored at 80°C
before measurement of tPA antigen, PAI-1 activity, and
antigen (Actibind), plasmin-antiplasmin (PAP) complexes
(all from Technoclone Ltd, Dorking, Surrey, UK), and
vWF activity (Axis-Shield UK, Cambridgeshire, UK).
Measurement of the platelet response. Flow cyto-
metric analysis of the platelet response was done in a
whole blood assay, as described previously.25 Briefly,
10 minutes of collection, 5 L of citrated blood was
added to 50 L of N-2-hydroxyethylpiperazine-N=-2-
ethanesulfonic acid (HEPES)-buffered saline containing
FITC-antifibrinogen antibody (Dako, Ely, UK) and ei-
ther thrombin (0.16 U/mL), thrombin receptor-activating
peptide (TRAP; 1  10–5M), or adenosine diphosphate
(ADP; 1  10–5M; all from Sigma-Aldrich Co Ltd,
Dorset, UK) and incubated for 20 minutes at room
temperature. Samples containing thrombin also con-
tained glycyl-L-prolyl-L-arginyl-L-proline (GPRP) pep-
tide (Sigma) to block fibrin cross-linking.26 The samples
were then diluted 100 times with formyl saline (0.2%
v/v), and flow cytometric analysis was done using a
Beckman-Coulter MCL-XL flow cytometer (Beckman-
Coulter Ltd, High Wycombe, UK). Negative controls
were set to 2% on samples incubated with antibody, in
the presence of ethylenediaminetetraacetic acid, which
prevents the binding of fibrinogen to glycoprotein (GP)
IIb-IIIa. To observe the effect of dextran on the whole
blood in vitro, 10% dextran-40 was also added to the
preoperation blood sample at a similar concentration (20
L/mL) to that being infused into the patients.
Platelet aggregation was measured in platelet-rich
plasma 1 hour of sampling. Platelet-rich plasma was pre-
pared from citrated plasma and stimulated with TRAP (2
10–5M), ADP (4  10–6M), or collagen (1.0 g/mL;
Horm collagen; Nycomed, Hart Biologicals, Hartlepool,
UK). Aggregation was measured for 10 minutes in a
PAP4C aggregometer (BioData Corp, Horsham, UK),
setting 100% transmission against autologous platelet-poor
plasma.
Statistical analysis. Two-way analysis of variance was
used to analyze differences between the two treatment
groups during the three time points studied. Post-test
analysis for comparison between time points was performed
using the Tukey multiple comparison test.RESULTS
Effects of dextran infusion on thrombus formed in
vitro. Dextran did not affect the weight of the thrombi
formed ex vivo, which were similar at all time points in both
the dextran- and saline-treated groups (P .05; Fig 1, A),
Fig 1. Chandler loop thrombus weight and lysis. Patients were
randomized to 100 mL of 10% dextran-40 (n  10; closed circles,
solid line) or 100 mL of saline (n  10; open circles, dashed line).
The data are shown as mean standard error of the mean. A, The
weight (in mg) of thrombi formed over 90 minutes. B, The
percentage reduction in thrombus weight over 24 hours. C, Re-
lease of fluorescein isothiocyanate-labelled fibrinogen from
thrombi over 24 hours as measured by release of fluorescence,
expressed as fluorescence units per mg initial thrombus weight.although a significant reduction was seen in the weight of
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ples in both groups, which was due to the effects of heparin
infusion during the operation. This fall was significant in
both groups, dropping from 38.0  5.9 mg to 12.0  3.6
mg in the saline-treated group (P  .01) and from 26.9 
2.3 mg to 10.5 4.2 mg (P .008) in the dextran-treated
group, but not different between the two groups. Throm-
bus formed from blood collected in the postoperative pe-
riod rose in both groups to preoperative weights.
Despite the similar initial thrombus weights, the
thrombi formed from blood taken after the dextran infu-
sion showed significantly increased fibrinolysis during a
24-hour period compared with the blood from the patients
who received saline. This was seen as both a greater fall in
thrombus weight, from 34.8  4.8 to 73.0  9.0 mg; a
change of 70.6%, in the dextran-treated group compared
with 31.3 1.6 to 46.8 9.1mg; a change of 34.7% in the
saline-treated group (P  .02; Fig 1, B), and as a greater
loss of fluorescently labelled fibrinogen from the thrombi
(P  .016; Fig 1, C). Fibrinolysis in the samples collected
on the morning after the operation had returned to preop-
erative levels in both groups. The levels of fibrinolysis seen
in the samples from the dextran-treated subjects were
equivalent to the effect of 6 to 7 g/mL rtPA added to
blood at the time the thrombus was formed in vitro (data
not shown).
Dextran added to the preoperative blood samples in
vitro had no effect on either the weight of the thrombus
that formed (36.7 8.6 mg compared with 34.0 8.5 mg
without dextran; P  .82) or the rate of fibrinolysis, as
measured by loss of fluorescently labelled fibrinogen
(0.69  0.44 U/mg compared with 0.60  0.32 U/mg
without dextran; P  .87).
Effects of dextran infusion of the fibrinolytic
system. Despite the increase in the rate of fibrinolysis, no
significant difference was noted in the levels of tPA antigen
in the blood of either group at any time point (Fig 2, A).
Because the assay used measured total tPA antigen, this
finding did not preclude a rise in active tPA, which normally
represents only 2% to 5% of the total tPA; the remaining
95% to 98% being bound to PAI-1.We therefore looked for
evidence of a change in the level of plasmin that would be
altered by an increase in tPA activity.
The presence of PAP complexes in the circulation
provides evidence of activation of plasminogen to plasmin
by tPA in vivo.27 PAP antigen levels were significantly
higher in the dextran-treated patients 24 hours after oper-
ation compared with preoperative levels (13.59  3.3
Fig 2. The effect of dextran-40 infusion on plasma levels of
fibrinolytic factors. Patients were randomized to 100 mL of 10%
dextran-40 (n  10; closed circles, solid line) or 100 mL of saline
(n  10; open circles, dashed line). The data are shown as mean 
standard error of the mean.A, Tissue plasminogen activator (tPA)
antigen. B, Plasmin-antiplasmin (PAP) antigen. C, Plasminogen
activator inhibitor type 1 (PAI-1) antigen. D, PAI-1 activity.
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in plasmin activity that was not seen in the saline group (Fig
2, B). Levels of PAI-1 antigen and activity increased signif-
icantly in both groups during the 24 hours studied (P 
.02), but this rise in activity was significantly greater in the
dextran group, reaching 38.16 U/mL compared with
22.75 U/mL PAI-1 activity in the saline group (P .037;
Fig 2, C and D).
Effects of dextran infusion on vWF activity. VWF
was measured in an enzyme-linked immunosorbent assay
(ELISA) that uses a monoclonal antibody to the GPIb
binding site on vWF and which can therefore be used as an
indirect assay for functionally active vWF.28 In line with
previous reports we found a significant decrease in vWF
activity at the intraoperative time point in the dextran
group (P  .02), which was not seen in those patients
receiving saline (P  .873). VWF activity increased signif-
icantly postoperatively in both groups (P  .002 and P 
.024, respectively), reflecting release from damaged vascu-
lar endothelial cells and/or an acute phase response. How-
ever, the level of vWF remained significantly lower in the
dextran-treated group (P  .008) compared with the
saline-treated patients (Fig 3).
Effects of dextran on platelets. Incubation of whole
blood with dextran in vitro had no significant effect on the
platelet response to ADP, TRAP, or thrombin (Fig 4),
measured as the binding of fibrinogen to activated GPIIb-
IIIa. This was in marked contrast to the effect of dextran on
platelets in vivo. Platelets in samples taken from the patients
showed a marked reduction in the response to thrombin
after infusion. Although a reduction in response was seen in
both groups that could be attributed to the effects of
heparin, the percentage of platelets binding fibrinogen in
the dextran group was significantly lower than in the saline
group (11.1%  2.5% vs 41.2%  12.3%; P  .022),
indicating an effect of dextran over and above the effect of
Fig 3. The effect of dextran-40 infusion on plasma levels of
functionally active von Willebrand factor (vWF). Patients were
randomized to 100 mL of 10% dextran-40 (n  10; closed circles,
solid line) or 100 mL of saline (n  10; open circles, dashed line).
The data are shown as mean  standard error of the mean.heparin in these patients (Fig 5, A).This difference in the response to thrombin was not
seen when platelets were stimulated with TRAP (Fig 5, B).
Although there was a significant difference in the response
to TRAP between the groups, this was seen at all time
points and appears to reflect an inherent characteristic of
the groups that was maintained from the preoperation time
point. No significant effect of dextran infusion was seen on
fibrinogen binding in response to ADP. Similarly, platelet
aggregation in response to ADP, collagen, or TRAP was
not significantly affected by dextran infusion (data not
shown). Aggregation in response to thrombin was not
measured in this study.
DISCUSSION
Clinically, dextran is used primarily as a plasma ex-
pander, yet there is clear evidence in the literature that it
also has an antithrombotic effect in vivo. This has proved
beneficial in the context of prevention of deep vein throm-
bosis29 and in carotid surgery, where it has been used to
treat patients with high levels of postoperative emboliza-
tion.30 By the systematic use of transcranial Doppler mon-
itoring to identify patients who generate high numbers of
emboli, targeted dextran treatment in these patients has
reduced the rate of postoperative thromboembolic compli-
cations to zero.5,21,30 In those patients who were treated
with a bolus of 20 mL of 10% dextran-40, followed by an
infusion of 20 to 40 mL of 10% dextran-40 per hour, the
rate of embolization fell rapidly within the first hour and
reached levels below the clinically defined threshold of 20
emboli per hour 2 to 3 hours.6 However despite the
clinical benefit, the antithrombotic mechanism of dextran is
Fig 4. Effect of dextran-40 on the response of platelets in vitro.
The percentage of platelets binding fibrinogen in response to
maximal stimulation with adenosine diphosphate (ADP) at 1 
10–5M, thrombin receptor activating peptide (TRAP) at 1 
10–5M, or thrombin at 0.16 U/mL, in the presence or absence
of 10% dextran-40 at a dose of 20 L/mL (n 3; P .05 for all).not well understood.
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years indicated that the antithrombotic effect of dextran
seen in vivo cannot be replicated in vitro.The various pieces
of evidence point to a number of potential modes of action
involving platelets,31 vWF,11-14 and the fibrinolytic sys-
tem.16-19 These disparate observations were clarified by the
report of Noorman et al,20 who demonstrated that in rats
dextran binds to the mannose receptor on endothelial cells
and in so doing blocks the uptake of tPA from the circula-
tion.
That tPA is a potent fibrinolytic agent in vivo is evi-
denced by the therapeutic benefit of rtPA and its derivatives
in restoring blood flow in occluded arteries.32 The level of
tPA in the blood is carefully controlled in a number of ways;
by regulated synthesis and release from the vascular endo-
thelium,33 through inhibition by binding to PAI-1, which
is present in the plasma in large excess, and by rapid
clearance in the liver.34 Two receptors for tPA are found in
the liver; the low-density lipoprotein (LDL) receptor-
related protein on liver parenchymal cells, and the mannose
receptor, which is found predominantly on liver sinusoidal
Fig 5. Effects of dextran infusion on platelet activity ex vivo.
Patients were randomized to 100 mL of 10% dextran-40 (n  10;
closed circles, solid line) or 100 mL of saline (n  10; open circles,
dashed line). Data are shown as mean  standard error of the
mean. The percentage of platelets binding fibrinogen was mea-
sured in response to A, thrombin (0.16 U/mL), and B, throm-
bin receptor-activating peptide (1  10–5).endothelial cells.35TPA is a serine protease that activates fibrinolysis by
converting plasminogen to plasmin. Small elevations in
levels of active tPA in plasma would lead to increased
generation of plasmin in vivo, which would have the effect
of enhancing fibrinolysis though the cleavage of cross-
linked fibrin by plasmin. However, plasmin has a number of
other substrates, including vWF36 and the platelet
protease-activated receptor-1 (PAR-1) thrombin receptor
on human platelets, leading to desensitization of the plate-
let response to thrombin.37 Cleavage of vWF multimers
and reduction of vWF-dependent shear-mediated platelet
interactions have been reported after thrombolytic therapy
with tPA.26,38
The present study allowed us to explore the mechanism
of dextran at the doses used to treat CEA patients and to
demonstrate clearly that the effect was systemic and associ-
ated with an increase in plasmin activity in vivo. Our find-
ings support a mechanism involving blockade of tPA up-
take by mannose receptors, previously demonstrated in
rats,19 and help to clarify the various somewhat disparate
findings of the other effects of dextran in the literature.
Thus, dextran infusion led to an increase in plasmin gener-
ation (evidenced by an increase in PAP complexes), result-
ing in increased fibrinolysis (evidenced by the increased
lysis of Chandler loop thrombi) as well as degradation of
vWF (as evidenced by reduced levels in the ELISA) and
desensitization of the platelet response uniquely to throm-
bin.
Together, these effects would have an overall anti-
thrombotic effect in vivo; higher levels of plasmin would
result in more rapid breakdown of thrombus that forms on
the carotid endarterectomy site, breakdown of vWF mul-
timers would have the dual effect of a reduction of platelet
adhesion to the vessel wall and loss of stability within the
thrombus (as reported by Aberg and Rausing14); cleavage
of the platelet PAR-1 receptor would lead to a loss of
response to thrombin, but not to other agonists, including
TRAP, because plasmin cleaves the thrombin activation
peptide from the PAR-1 receptor but not its ligand binding
site.37
Although we did not detect a rise in the level of tPA in
the patients, this can be explained by the short half-life of
both free tPA and the tPA-PAI-1 complex in vivo, which is
of the order of 5 to 6 minutes.35,39 For example, in the
study of Noorman et al in rats,20 the rise in endogenous
tPA after dextran infusion had dropped to baseline levels by
45 minutes. However, there was good indirect evidence of
the effects of an elevation in tPA, indicated by the rise in
plasmin-antiplasmin complexes, which are a marker of a
previous rise in plasmin.27 Because these complexes have a
longer plasma half-life than tPA,40 they were more readily
detectable. Although this observation, and the significant
increased levels of PAI-1 antigen, would seem to contradict
the findings of Eriksson and Saldeen,19 who saw a rise in
tPA and a fall in PAI-1 in patients receiving dextran-70
during surgery, the timing of the samples differed from the
present study. The rise in PAI-1 that we observed in the
postoperative samples in the dextran- but not saline-treated
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tPA. Overall, these increases in PAI-1 did not contribute to
a reduction in fibrinolysis, which returned to preoperative
levels in both groups in the postoperative samples.
The maximal effect of dextran has been reported to be
seen at 4 to 6 hours11,13; thus, the effect seen in the present
study after an infusion of 1 hour may be submaximal.
Despite this, 1 hour of infusion of low-dose dextran-40
produced a 13-fold increase in ex vivo fibrinolysis, which is
comparable to the effect of 6 to 7 g/mL rtPA added to
the blood before thrombus formation. It would be inter-
esting to analyze the blood at more time points after
infusion, to monitor the time course of fibrinolysis
through the appearance of fibrin degradation products
and D-dimer, and to look directly at the cleavage of
platelet PAR-1 and vWF multimers, but multiple sam-
pling was not possible in this patient group. A more
detailed study of the effects of dextran in volunteers, in
the absence of confounding clinical and therapeutic fac-
tors, may be warranted.
CONCLUSION
Our findings provide a mechanistic explanation for the
beneficial effects of dextran in reducing thromboembolic
events in patients undergoing CEA. They also suggest that
these low doses of dextran may provide a useful, low-cost
adjunct to other therapies for reducing thromboembolic
complications.
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